A ๐งต on chest Xray signs in pulmonary thromboembolism.
The ๐๐น๐ฒ๐ถ๐๐ฐ๐ต๐ป๐ฒ๐ฟ ๐๐ถ๐ด๐ป is a prominent central artery that can be caused either by pulmonary hypertension or by distension of the vessel by a large pulmonary embolus seen on chest x ray.
๐๐ฎ๐บ๐ฝ๐๐ผ๐ป ๐ต๐๐บ๐ฝ refers to a dome-shaped, pleural-based opacification in the lung most commonly due to pulmonary embolism and lung infarction (it can also result from other causes of pulmonary infarction (e.g. vascular occlusion due to angioinvasive aspergillosis)
The focal area of increased translucency due to oligaemia is caused by impaired vascularisation of the lung due to primary mechanical obstruction or reflex vasoconstriction.
The ๐๐ป๐๐ฐ๐ธ๐น๐ฒ ๐๐ถ๐ด๐ป refers to the abrupt tapering or cutoff of a pulmonary artery secondary to a pulmonary embolus (PE).
This is an important ancillary finding in pulmonary embolism, and often associated with the Fleischner sign of dilated central pulmonary arteries.
A summary of things till now๐
๐ฃ๐ฎ๐น๐น๐ฎ's ๐๐ถ๐ด๐ป :
Clinical sign in which an enlarged right descending pulmonary artery is seen on the chest x-ray in patients with pulmonary embolism
๐๐ต๐ฎ๐ป๐ด ๐๐ถ๐ด๐ป on CXR describes a dilated left or right descending pulmonary artery with an abrupt change in calibre, with an amputated appearance.
This sign is most commonly associated with with pulmonary infarction and pulmonary hypertension following pulmonary embolism
๐ฅSmith ๐ฆ๐ต ๐ข๐ญ. reported draining a world record of 41 ๐น๐ถ๐๐ฟ๐ฒ๐ of ascitic fluid in a single paracentesis session of a patient with decompensated cirrhosis.
How much Albumin would be needed in this case to prevent post paracentesis circulatory dysfunction ? ๐งต Read on๐
A ๐งต on important points to consider while performing Large Volume Paracentesis (LVP)
๐Large Volume Paracentesis(LVP)
is arbitrarily defined as a paracentesis with >5 L of ascitic fluid drained.
In patients undergoing LVP, the use of albumin is crucial to prevent a further reduction of effective arterial blood volume, which may precipitate postparacentesis circulatory dysfunction (PPCD).
The clinical manifestations of PPCD include renal impairment, including HRS, dilutional hyponatremia, hepatic encephalopathy and death.
Albumin infusion is particularly important if more than 5 L of ascites are removed to prevent the development of PPCD.
Paracenteses of a smaller volume(<5L) are not associated with significant hemodynamic changes and albumin infusion may not be required.
Although there has not been a doseโresponse study on albumin use with LVP, the administration of 6โ8 g of albumin per liter of ascites removed has been recommended.
๐ฅFor example, after the fifth liter, approximately 40 g of albumin should be infused, and after 8 L removal, the amount of albumin given should be approximately 64 g.
It has been held that there is no limit for the amount of ascites that can be removed in a single session, provided an appropriate amount of albumin is administered.
However, the risk of PPCD increases with >8 L of fluid evacuated in one single session.
A study showed that by limiting the LVP volume to <8 L per session and providing a higher than recommended dose of albumin (9.0 ยฑ 2.5 g per liter of ascites removed), renal function and survival may be better preserved over a mean period of 2 years despite the development of PPCD in 40% of patients.
In patients with hemodynamic instability (systolic blood pressure <90 mm Hg), hyponatremia (serum sodium <130 mmol/L), and/or the presence of AKI, albumin infusion should be strongly considered for paracentesis of a smaller volume.
LVP is a safe procedure even in the presence of coagulopathy. In a study that included patients with an international normalized ratio of >1.5 and a platelet count of <50 ร 109/L, only 1% of patients experienced minimal cutaneous bleeding after LVP.
Therefore, elevated prothrombin time or thrombocytopenia is not a contraindication for paracentesis, nor is transfusion of clotting factors or platelets recommended.
Possible exceptions may include patients with disseminated intravascular coagulation or uremia with thrombocytopenia.
1/3 ๐ ๐พ๐ค๐ฃ๐ฉ.
๐ฅIdeal site for needle insertion in abdominal paracentesis
๐ธ๏ธMalar rash is classically described in SLE as a "butterfly" shaped erythematous rash in the malar distribution, which includes the cheeks and crosses the nasal bridge but spares the nasolabial folds.
Let's look at the mimickers๐
Do read the whole๐งต
๐ Systemic Lupus Erythematosus
๐ธ๏ธClassic finding in SLE
๐ธ๏ธThe ORIGINAL Malar Rash๐ฆ
From Kelley's Textbook of Rheumatology, 9e
๐ ACNE ROSACEA
A common chronic inflammatory acneiform disorder of the facial pilosebaceous units.
An increased reactivity of capillaries leading to flushing and telangiectasia.
May result in rubbery thickening of nose, cheeks, forehead, or chin due to sebaceous hyperplasia.
There is โ๏ธ NO convincing evidence that the use of SGLT-2 inhibitors is associated with an increased risk of UTI according to this expert consensus statement. (PMID- 37153973)
Concerns about UTIs should not be a deterrent to initiating SGLT-2i...๐
โซ๏ธIn patients with T2DM and atherosclerotic risk factors, SGLT-2i should be used for its organ protective benefits such as reducing the risk of hospitalization for heart failure and kidney disease progression, regardless of glycemic control.
โซ๏ธSimilarly, in patients who have chronic kidney disease with or without diabetes, SGLT-2i should be initiated for kidney and heart protective benefits.